Omalizumab dosing via the recommended card versus use of the published formula [4]

Journal of Allergy and Clinical Immunology

Volumn 117, Issue 3, 2006, Pages 708-709

  Rambasek, Todd ^a   Kavuru, Mani S ^b  

^a ENT Health Services Inc   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ASTHMA; DOSE CALCULATION; DRUG BINDING; DRUG COST; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MATHEMATICAL COMPUTING; METHODOLOGY; PHARMACODYNAMICS; POCKET CALCULATOR; PRIORITY JOURNAL;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HUMANS; IMMUNOGLOBULIN E; RETROSPECTIVE STUDIES;

EID: 33644785681     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2005.11.042     Document Type: Letter

References (3)

1. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
2. L. Borish, C. Bradley, D. Yamo, S. Gujrathi, B. Zheng, and C.M. Dolan Total serum IgE levels in a large cohort of patients with severe or difficult to treat asthma Ann Allergy Asthma Immunol 108 2005 184 253
3. T. Rambasek, D. Lang, and M. Kavuru Omalizumab: where does it fit into current asthma management? Cleve Clin J Med 71 2004 251 261